Vector provides clinical trial and biotechnology support by supplying a collection of bio-samples, including tissues, bio-fluids, and living cells. The company utilizes technology and logistics expertise to facilitate rapid sourcing, preservation, and indexing of these samples for researchers, testing laboratories, and equipment manufacturers. Vector intends to expand this division through organic growth and acquisitions.
FOXO Labs, a subsidiary specializing in epigenetics, develops epigenetic biomarkers and offers advanced epigenetic testing services and bioinformatic tools using saliva-based samples. FOXO Labs focuses on bioinformatics services and research and development in health and wellness testing, employing machine learning and artificial intelligence. The company holds two patents related to machine learning techniques for commercializing epigenetic biomarkers.
The development and commercialization of FOXO Labs' epigenetics business require significant additional capital, which has not yet been obtained, resulting in a full impairment of intangible assets in this division. Potential future strategies for this business include partnerships, joint ventures, or sale, though no decisions have been finalized.
Foxo Technologies Inc's Comment on Supply Chain
Vector provides clinical trial and biotechnology support by supplying a collection of bio-samples, including tissues, bio-fluids, and living cells. The company utilizes technology and logistics expertise to facilitate rapid sourcing, preservation, and indexing of these samples for researchers, testing laboratories, and equipment manufacturers. Vector intends to expand this division through organic growth and acquisitions.
FOXO Labs, a subsidiary specializing in epigenetics, develops epigenetic biomarkers and offers advanced epigenetic testing services and bioinformatic tools using saliva-based samples. FOXO Labs focuses on bioinformatics services and research and development in health and wellness testing, employing machine learning and artificial intelligence. The company holds two patents related to machine learning techniques for commercializing epigenetic biomarkers.
The development and commercialization of FOXO Labs' epigenetics business require significant additional capital, which has not yet been obtained, resulting in a full impairment of intangible assets in this division. Potential future strategies for this business include partnerships, joint ventures, or sale, though no decisions have been finalized.
Sources:
Foxo Technologies Inc 's official press releases and regulatory filings; CSIMarket.com's supply-chain research; and the financial filings and press releases of other companies cited in this report.
Updated on:
For your research, we’ve provided nine additional tables on Foxo Technologies Inc ’s suppliers.
You can find them in the navigation menu under Suppliers.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
